The Ambivalent Role of MiRNAs in Carcinogenesis: Involvement in Renal Cell Carcinoma and Their Clinical Applications

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2021 Apr 30

PMID 33918154

Citations 10

Authors

Federica Spadaccino

Margherita Gigante

Giuseppe Stefano Netti

Maria Teresa Rocchetti

Rossana Franzin

Loreto Gesualdo

Giuseppe Castellano

Giovanni Stallone

Elena Ranieri

Affiliations

Soon will be listed here.

Abstract

The analysis of microRNA (miRNAs), small, non-coding endogenous RNA, plays a crucial role in oncology. These short regulatory sequences, acting on thousands of messenger RNAs (mRNAs), modulate gene expression at the transcriptional and post-transcriptional level leading to translational repression or degradation of target molecules. Although their function is required for several physiological processes, such as proliferation, apoptosis and cell differentiation, miRNAs are also responsible for development and/or progression of several cancers, since they may interact with classical tumor pathways. In this review, we highlight recent advances in deregulated miRNAs in cancer focusing on renal cell carcinoma (RCC) and provide an overview of the potential use of miRNA in their clinical settings, such as diagnostic and prognostic markers.

Citing Articles

The role of natural products versus miRNA in renal cell carcinoma: implications for disease mechanisms and diagnostic markers.

Ayed A Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(9):6417-6437.

PMID: 38691151 DOI: 10.1007/s00210-024-03121-8.

KL is a favorable prognostic factor related immune for clear cell renal cell carcinoma.

Pan K, Yao L, Chen Z, Sun J, Jia Z, Zhang J Eur J Med Res. 2023; 28(1):356.

PMID: 37726833 PMC: 10510209. DOI: 10.1186/s40001-023-01242-z.

Chasing the Role of miRNAs in RCC: From Free-Circulating to Extracellular-Vesicle-Derived Biomarkers.

Mastrolia I, Catani V, Oltrecolli M, Pipitone S, Vitale M, Masciale V Biology (Basel). 2023; 12(6).

PMID: 37372161 PMC: 10295314. DOI: 10.3390/biology12060877.

Critical Evaluation of a microRNA-Based Risk Classifier Predicting Cancer-Specific Survival in Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava.

Kotlyar M, Krebs M, Solimando A, Marquardt A, Burger M, Kubler H Cancers (Basel). 2023; 15(7).

PMID: 37046643 PMC: 10093292. DOI: 10.3390/cancers15071981.

The Emerging Role of MicroRNAs and Autophagy Mechanism in Pancreatic Cancer Progression: Future Therapeutic Approaches.

Koustas E, Trifylli E, Sarantis P, Papadopoulos N, Papanikolopoulos K, Aloizos G Genes (Basel). 2022; 13(10).

PMID: 36292753 PMC: 9602304. DOI: 10.3390/genes13101868.

References

Redfern A, Colley S, Beveridge D, Ikeda N, Epis M, Li X . RNA-induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulators. Proc Natl Acad Sci U S A. 2013; 110(16):6536-41. PMC: 3631673. DOI: 10.1073/pnas.1301620110. View

Arroyo J, Chevillet J, Kroh E, Ruf I, Pritchard C, Gibson D . Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011; 108(12):5003-8. PMC: 3064324. DOI: 10.1073/pnas.1019055108. View

Andrade F, Nakata A, Gotoh N, Fujita A . Large miRNA survival analysis reveals a prognostic four-biomarker signature for triple negative breast cancer. Genet Mol Biol. 2019; 43(1):e20180269. PMC: 7198019. DOI: 10.1590/1678-4685-GMB-2018-0269. View

Loverre A, Capobianco C, Stallone G, Infante B, Schena A, Ditonno P . Ischemia-reperfusion injury-induced abnormal dendritic cell traffic in the transplanted kidney with delayed graft function. Kidney Int. 2007; 72(8):994-1003. DOI: 10.1038/sj.ki.5002468. View

Heinemann F, Tolkach Y, Deng M, Schmidt D, Perner S, Kristiansen G . Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma. Clin Epigenetics. 2018; 10:11. PMC: 5781339. DOI: 10.1186/s13148-018-0444-9. View

Gigante M, Lucarelli G, Divella C, Netti G, Pontrelli P, Cafiero C . Soluble Serum αKlotho Is a Potential Predictive Marker of Disease Progression in Clear Cell Renal Cell Carcinoma. Medicine (Baltimore). 2015; 94(45):e1917. PMC: 4912252. DOI: 10.1097/MD.0000000000001917. View

Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637. PMC: 7251107. DOI: 10.1038/s41416-020-0802-1. View

Toraih E, Ibrahiem A, Fawzy M, Hussein M, Al-Qahtani S, Shaalan A . MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma. Oxid Med Cell Longev. 2017; 2017:3269379. PMC: 5632457. DOI: 10.1155/2017/3269379. View

Li J, Zhang Z, Chen F, Hu T, Peng W, Gu Q . The Diverse Oncogenic and Tumor Suppressor Roles of microRNA-105 in Cancer. Front Oncol. 2019; 9:518. PMC: 6595394. DOI: 10.3389/fonc.2019.00518. View

10.

Wang W, Hu W, Wang Y, Yang J, Yue Z . MicroRNA-508 is downregulated in clear cell renal cell carcinoma and targets ZEB1 to suppress cell proliferation and invasion. Exp Ther Med. 2019; 17(5):3814-3822. PMC: 6447938. DOI: 10.3892/etm.2019.7332. View

11.

Lou N, Ruan A, Qiu B, Bao L, Xu Y, Zhao Y . miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma. Urol Oncol. 2016; 35(1):36.e7-36.e14. DOI: 10.1016/j.urolonc.2016.07.012. View

12.

Li H, Li J, Wang Z, Fu D, Li Z, Zhang D . Identification of angiogenesis-related miRNAs in a population of patients with renal clear cell carcinoma. Oncol Rep. 2014; 32(5):2061-9. DOI: 10.3892/or.2014.3403. View

13.

Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R . Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012; 10:55. PMC: 3340316. DOI: 10.1186/1479-5876-10-55. View

14.

Li Y, Guan B, Liu J, Zhang Z, He S, Zhan Y . MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma. EBioMedicine. 2019; 44:439-451. PMC: 6604878. DOI: 10.1016/j.ebiom.2019.05.041. View

15.

Cochetti G, Cari L, Nocentini G, Maula V, Suvieri C, Cagnani R . Detection of urinary miRNAs for diagnosis of clear cell renal cell carcinoma. Sci Rep. 2020; 10(1):21290. PMC: 7718885. DOI: 10.1038/s41598-020-77774-9. View

16.

Hatzl S, Geiger O, Kuepper M, Caraffini V, Seime T, Furlan T . Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP. Cancer Res. 2016; 76(12):3644-54. PMC: 5024755. DOI: 10.1158/0008-5472.CAN-15-3049. View

17.

Vavallo A, Simone S, Lucarelli G, Rutigliano M, Galleggiante V, Grandaliano G . Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma. Medicine (Baltimore). 2014; 93(27):e183. PMC: 4602816. DOI: 10.1097/MD.0000000000000183. View

18.

Wang N, Cao Y, Ge X, Nie J, Yu Y, Li Q . MicroRNA-195 as a prognostic factor for cancer survival outcome in China: a meta-analysis. Cancer Manag Res. 2019; 11:7967-7979. PMC: 6709821. DOI: 10.2147/CMAR.S205841. View

19.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

20.

Huang Q, Ma X, Zhang X, Liu S, Ai Q, Shi T . Down-Regulated miR-30a in Clear Cell Renal Cell Carcinoma Correlated with Tumor Hematogenous Metastasis by Targeting Angiogenesis-Specific DLL4. PLoS One. 2013; 8(6):e67294. PMC: 3694928. DOI: 10.1371/journal.pone.0067294. View